A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.-MedSci.cn

A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.

Calles, A; Navarro, A; Doger, B; de Miguel, MJ; Alvarez, RMA; Moreno, V; Ramon, J; Lopez, MDMG; Hernandez-Guerrero, T; Corral, E; Calvo, E

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务